INS018_055

INS018_055, an AI-discovered antifibrotic drug, enters Phase II trials for Idiopathic Pulmonary Fibrosis (IPF), with promising safety and tolerability data from Phase I. The trials, conducted in China and the US, aim to validate the drug's effectiveness in treating IPF, a disease with significant economic impact.

Insilico Medicine's Phase 2a trial for ISM001-055, an AI-developed TNIK inhibitor targeting IPF, shows promising results, addressing both fibrosis and inflammation. The trial enrolled 71 IPF patients across 21 sites in China, with findings published in *Nature Biotechnology*. The company plans to publish and present results, aiming for a global Phase IIb study.

Insilico Medicine's lead candidate drug, INS018_055/ISM001-055, met safety and efficacy endpoints in a phase 2a trial for idiopathic pulmonary fibrosis (IPF), with highest dose showing significant improvement in lung function. The company plans a phase 2b trial and will release full data at a medical conference. Insilico specializes in AI-driven drug discovery, with this being the first AI-designed drug to enter phase 2 trials.